洛铂联合紫杉醇治疗晚期非小细胞肺癌的疗效与安全性研究

Abstract
Figure/Table
References (16)
Related Citation (15)

Download: PDF (0 KB) HTML (37 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the clinical efficacy of Lobaplatin plus Paclitaxel treating advanced non-small cell lung cancer,and to explore the clinical applicability.M ethods From March 2015 to June 2016,40 cases of new advanced non-small cell lung cancerwere collected as study object from Xiaolan Town in Zhongshan City of Guangdong Province and randomly divided into the control group and the observation group,each group had 20 cases.The control group was treated with Paclitaxel plus Carboplatin,the observation group was treated with Paclitaxel plus Lobaplatin.The clinical efficacy and the incidence of adverse reaction after treatment between two groups were compared.Results The total effective rate of the control group was 70.00％and itwas obviously lower than that of the observation group(95.00％),and the difference was statistically significant(P＜0.05).The incidence of adverse reaction of the observation group was obviously lower than that of the control group,the differencewas statistically significant(P＜0.05).Conclusion The efficacy of Lobaplatin plus Paclitaxel treating advanced non-small cell pulmonary cancer is notable,the incidence of adverse reactions is lower,which isworthy of clinical promotion and application.

Key words： Lobaplatin Carboplatin Paclitaxel Drug resistance non-small cell lung cancer Chemotherapy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WEIShu-li
	ZHU Mo-shou
	LIU Zhen-hai
	LIN Shu-mei
	FENGQi-xiao

Cite this article:

WEIShu-li,ZHU Mo-shou,LIU Zhen-hai, et al. The study of the efficacy and safety of Lobap latin p lus Paclitaxel treating advanced non-small cell lung cancer[J]. 中国当代医药, 2016, 23(32): 73-75.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2016/V23/I32/73

[5]	孙燕，石元凯.实体瘤疗效标准.临床肿瘤内科手册[M].5版.北京：人民卫生出版社，2007：150-153.
[6]	刘红艳，鲁启洪.紫杉醇联合卡铂治疗非小细胞肺癌90例临床观察与护理[J].中外健康文摘，2014，8（22）：230.
[7]	张琼，刘培强，李林，等.培美曲塞、吉西他滨联合卡铂治疗老年晚期非小细胞肺癌临床观察[J].山东医药，2013，53（43）：37-38.
[8]	解明德，王理想，陈春芬，等．洛铂诱导人肺腺癌A549细胞凋亡机制的实验研究[J].滨州医学院学报，2013，36（2）：81-85．
[1]	徐经芳.培美曲塞联合顺铂与吉西他滨联合顺铂治疗晚期非小细胞肺癌的临床研究[J].现代肿瘤医学，2014，22（7）：1572-1574.
[2]	潘学兵，李壮华，贾筠，等.培美曲赛加卡铂对照吉西他滨加卡铂二线联合化疗晚期非小细胞肺癌疗效分析研究[J].中国当代医药，2011，18（17）：81-82.
[3]	唐俊舫，吴羽华，武玮，等.贝伐珠单抗联合紫杉醇/卡铂方案治疗晚期非小细胞肺癌的临床疗效分析[J].现代生物医学进展，2013，13（12）：2305-2309.
[4]	Zabel R，Kullmann M，Kalayda GV，et al.Optimized sample preparation strategy for the analysis of low molecylar mass ad-ducts of a fluorescent cisplatin analogue in cancer cell lines by CE-dual-LIF[J].Electrophoresis，2015，36（4）：509-517.
[9]	宛新安，周勤，韦永明.多西他赛单药或联合顺铂在分子靶向治疗失败的非小细胞肺癌中的临床应用研究[J].临床肺科杂志，2015，20（3）：405-408.
[10]	娄娜娜，杨衿记，严红虹，等.吉非替尼与紫杉醇联合卡铂治疗晚期肺腺癌患者的效果分析[J].中华医学杂志，2014，94（30）：2337-2341.
[11]	邬麟，王倩之，曹军，等.多西他赛联合洛铂二线治疗晚期非小细胞肺癌的临床研究[J].中国肿瘤临床与康复，2013，20（10）：1092-1096.
[12]	吴月明.洛铂或顺铂联合吉西他滨治疗晚期非小细胞肺癌的疗效分析[J].中国医师进修杂志，2013，36（17）：66-67.
[13]	王智辉，刘裕杰，吴庭安，等.培美曲塞联合卡铂与吉西他滨联合卡铂治疗非小细胞肺癌的疗效对比研究[J].广西医学，2013，35（8）：1000-1002.
[14]	Manegold C，Drings P，Gatzemeier U，et al.Lobaplatin（D-19466）in patients with advanced non-small cell lung cancer：a trial of the Association for Medical Oncology（AIO）PhaseⅡStudy Group[J].Onkologie，1996，19（3）：248-251.
[15]	Li KW，Li X，Wen TF，et al.The effect of postoperative-TACE on prognosis of HCC：an update[J].Hepatogastroenterology，2013，60（122）：248.
[16]	朱彦博，王振欣，熊峰，等.培美曲塞与吉西他滨分别联合卡铂对老年晚期NSCLC的疗效对比及安全性评价[J].中国生化药物杂志，2014，8（4）：145-147.